USA AI in Life Sciences Market Expands as IQVIA Rolls Out New Agents, Tracking Global Rise from USD 17.6 billion in 2026 to USD 81.1 billion by 2036 at 16.5% CAGR

ROCKVILLE, MARYLAND , August 6, 2026 - The artificial intelligence in life sciences market was valued at USD 15.1 billion in 2025 and is projected to grow from USD 17.6 billion in 2026 to USD 81.1 billion by 2036, recording a compound annual growth rate of 16.5% during the forecast period. (Note: one section of the source report states a 2036 value of USD 81.3 billion; the primary forecast figure of USD 81.1 billion is used here, with the absolute opportunity cited as USD 63.7 billion.)

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/report/artificial-intelligence-in-life-sciences-market

Key Findings

Market value exceeded USD 15.1 billion in 2025.
Demand projected to rise from USD 17.6 billion in 2026 to USD 81.1 billion by 2036.
CAGR of 16.5% from 2026 to 2036.
Absolute opportunity of USD 63.7 billion by 2036.
Life sciences organizations use AI software and related services for discovery, clinical research, precision medicine, regulatory review, safety work, and commercial operations where human review of output is possible.

Growth Drivers

Pharmaceutical research teams require faster target and compound ranking due to limited laboratory time.
Clinical development teams need current site and patient data before protocol decisions.
Precision medicine programs require traceable genomic evidence for reviewable patient subgroups.
AI-ready biomedical and clinical data programs support adoption in North America and Europe (medium term, 2-4 years).
Drug discovery and preclinical workflow integration supports adoption in the USA, UK, Germany, and Switzerland (medium term, 2-4 years).
Clinical trial optimization and patient matching supports adoption in the USA, UK, and Japan (short to medium term).
Precision medicine and multi-omics analysis supports adoption in the USA, Switzerland, and Canada (long term, ≥4 years).
Regulatory guidance for defined AI contexts of use supports adoption in the USA, Europe, and UK (short term, ≤2 years).

Segment Analysis by Product, Technology, and Application

By AI Solution

Drug Discovery Platforms expected to hold 40% share in 2026, used for target identification and lead optimization.
Other segments: Clinical Research Intelligence; Precision Medicine Solutions; Regulatory & Compliance Analytics.

By Life Sciences Function

Drug Discovery & Development projected to account for 39% share in 2026.
Other segments: Clinical Development; Genomics & Biomarker Research; Commercial Operations.

By Application Area

Pharmaceutical Research anticipated to capture 42% share in 2026.
Other segments: Clinical Trials; Precision Medicine; Regulatory Affairs.

By End User

Pharmaceutical Companies estimated to represent 44% share in 2026.
Other segments: Contract Research Organizations; Diagnostic Laboratories; Life Sciences Consulting Firms.

By Artificial Intelligence Technology

Machine Learning forecast to account for 39% share in 2026, applied to molecular data and clinical records.
Other technologies: Natural Language Processing; Computer Vision; Predictive Analytics; Explainable Artificial Intelligence.

Country-Level Growth Comparison

Country

CAGR (2026-2036)

Commercial Condition

USA

17.9%

Pharmaceutical R&D scale and governed AI adoption

UK

17.2%

Clinical research depth and medicines-regulation experimentation

Germany

16.6%

Pharmaceutical research and disciplined validation practices

Switzerland

16.0%

Pharmaceutical concentration and precision medicine infrastructure

Japan

15.5%

Coordinated medical research and translational science

Singapore

14.9%

Translational infrastructure and regional partnerships

Canada

14.3%

AI research and genomics capability

The country comparison spans 3.6 percentage points. The USA remains 0.7 percentage point above the UK; the UK remains 0.6 percentage point above Germany; Germany remains 0.6 percentage point above Switzerland; Switzerland remains 0.5 percentage point above Japan; Japan remains 0.6 percentage point above Singapore; Singapore remains 0.6 percentage point above Canada.

Competitive Landscape

Key companies profiled include:

IQVIA Holdings Inc.
Microsoft Corporation
Oracle Corporation
International Business Machines Corporation
NVIDIA Corporation
Schrödinger, Inc.
Tempus AI, Inc.
Recursion Pharmaceuticals, Inc.
Insilico Medicine
BenevolentAI

IQVIA Holdings Inc. has relevance through clinical research services and healthcare data. Microsoft and Oracle support life sciences workflows through cloud tools. IBM and NVIDIA provide computing support. Schrödinger and Tempus AI extend specialist scientific workflows. Insilico Medicine and BenevolentAI add discovery depth.

Recent Developments

European Medicines Agency published a Reflection paper on the use of Artificial Intelligence in the medicinal product lifecycle on September 9, 2024.
IQVIA launched new AI agents for life sciences and healthcare on June 11, 2025.
Medicines and Healthcare products Regulatory Agency launched an AI sandbox to accelerate medicines development and improve safety on June 9, 2026.
Recursion Pharmaceuticals, Inc. and Exscientia combined on November 20, 2024, to advance the industrialization of drug discovery.
U.S. Food and Drug Administration proposed a Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions on January 6, 2025.

Restraints

Model credibility and context-of-use validation slows approval (global regulated life sciences; short to medium term).
Fragmented and non-interoperable biomedical data raises integration cost (global; medium term, 2-4 years).
Privacy, consent, and cross-border data controls limit data reuse (Europe, Switzerland, and Canada; medium term, 2-4 years).
Limited reproducibility and model-change governance delays scale-up (global research and regulatory teams; long term, ≥4 years).

How to Choose: Buyer Decision Guide

Define the decision and evidence standard before models enter regulated work (pharmaceutical companies).
Evaluate predictions against real site capacity before applying them to protocol planning (clinical teams).
Preserve data history so genomic and biomarker findings remain reviewable (precision medicine teams).
Prefer platforms that retain decision history from target review into study design and regulatory documents.
Require clear system boundaries and documentation of model changes before enterprise expansion.
Confirm performance within a defined use case and support for secure data exchange where required by local privacy rules.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/artificial-intelligence-in-life-sciences-market

Report Scope

The report covers artificial intelligence software and related services used to support defined scientific, clinical, regulatory, safety, and commercial workflows across life sciences organizations. Segments include AI Solution (Drug Discovery Platforms; Clinical Research Intelligence; Precision Medicine Solutions; Regulatory & Compliance Analytics), Life Sciences Function, Application Area, End User, Artificial Intelligence Technology, and Region (North America; Latin America; Europe; East Asia; South Asia and Pacific; Middle East and Africa). Countries covered: USA; UK; Germany; Switzerland; Japan; Singapore; Canada. Forecast period: 2026 to 2036. Analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

Explore More Related Studies Published by Fact.MR Research

Acinetobacter Pneumonia Therapeutics Market https://www.factmr.com/report/acinetobacter-pneumonia-therapeutics-market

AI Drug Repurposing Market https://www.factmr.com/report/ai-drug-repurposing-market

Drug Reference Apps Market https://www.factmr.com/report/drug-reference-apps-market

Erythropoietin (EPO) Drugs Market https://www.factmr.com/report/erythropoietin-epo-drugs-market

Solid Tumor Testing Market https://www.factmr.com/report/solid-tumor-testing-market

Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination.

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.